Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Theravance Biopharma Inc (NASDAQ: TBPH) closed at $9.42 up 1.95% from its previous closing price of $9.24. In other words, the price has increased by $1.95 from its previous closing price. On the day, 0.26 million shares were traded. TBPH stock price reached its highest trading level at $9.44 during the session, while it also had its lowest trading level at $9.25.
Ratios:
For a deeper understanding of Theravance Biopharma Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.97 and its Current Ratio is at 4.97. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on August 06, 2024, Downgraded its rating to Market Perform and sets its target price to $10 from $15 previously.
On April 12, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $21.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 11 ’24 when Farnum Rhonda sold 4,000 shares for $9.00 per share. The transaction valued at 36,000 led to the insider holds 322,743 shares of the business.
Samaha Eli bought 999,800 shares of TBPH for $7,798,440 on Aug 07 ’24. The 10% Owner now owns 9,511,150 shares after completing the transaction at $7.80 per share. On Jul 10 ’24, another insider, Farnum Rhonda, who serves as the SVP, COMM & MEDICAL AFFAIRS of the company, sold 4,000 shares for $9.00 each. As a result, the insider received 36,000 and left with 335,965 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TBPH now has a Market Capitalization of 463221920 and an Enterprise Value of 411361952. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.33 while its Price-to-Book (P/B) ratio in mrq is 2.50. Its current Enterprise Value per Revenue stands at 6.51 whereas that against EBITDA is -10.758.
Stock Price History:
Over the past 52 weeks, TBPH has reached a high of $11.71, while it has fallen to a 52-week low of $7.44. The 50-Day Moving Average of the stock is 8.96%, while the 200-Day Moving Average is calculated to be 6.67%.
Shares Statistics:
For the past three months, TBPH has traded an average of 198.71K shares per day and 264560 over the past ten days. A total of 48.09M shares are outstanding, with a floating share count of 45.32M. Insiders hold about 7.85% of the company’s shares, while institutions hold 93.40% stake in the company. Shares short for TBPH as of 1731628800 were 4852704 with a Short Ratio of 24.42, compared to 1728950400 on 5036784. Therefore, it implies a Short% of Shares Outstanding of 4852704 and a Short% of Float of 19.17.
